TY  - JOUR 
AU  - Bearz, A.
AU  - Martini, J.-F.
AU  - Jassem, J.
AU  - Kim, S.-W.
AU  - Chang, G.-C.
AU  - Shaw, A.T.
AU  - Shepard, D.A.
AU  - Dall'O, E.
AU  - Polli, A.
AU  - Thurm, H.
AU  - Zalcman, G.
AU  - García Campelo, María del Rosario
AU  - Penkov, K.
AU  - Hayashi, H.
AU  - Solomon, B.J.
PY  - 2023
SN  - 1556-1380
UR  - http://hdl.handle.net/20.500.11940/21427
AB  - Introduction: Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, improved outcomes compared with crizotinib in patients with previously untreated ALK-positive advanced NSCLC in the phase 3 CROWN study. Here, we investigated response...
LA  - eng
KW  - Humans
KW  - Crizotinib
KW  - Lung Neoplasms
KW  - Antineoplastic Agents
KW  - Anaplastic Lymphoma Kinase
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Lactams, Macrocyclic
KW  - Protein Kinase Inhibitors
KW  - Mutation
KW  - Tumor Suppressor Protein p53
TI  - Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations
DO  - 10.1016/j.jtho.2023.07.023
T2  - Journal of Thoracic Oncology
M2  - 1581
KW  - AS A Coruña
KW  - CHUAC
VL  - 18
ER  -